Evidence map›Paper›PMID 11422193›Full record

ArticleClinical and experimental immunology2001

Membrane cofactor protein (MCP; CD46) expression in transgenic mice.

C Kemper, M Leung, C B Stephensen, C A Pinkert, M K Liszewski, R Cattaneo, J P Atkinson

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 115 citations in OpenAlex.

  1. Measles virus for cancer therapy.Current topics in microbiology and immunology · 2009
    Trial
  2. Review
  3. Article
  4. Molecular therapy. Advances · 2026
    Article
  5. Cross-species protection suggestsInfection and immunity · 2025
    Article
  6. Molecular therapy. Methods & clinical development · 2025
    Article
  7. The multiverse of CD46 and oncologic interactions.The Journal of clinical investigation · 2025
    Review
  8. Article
  9. Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  10. Auto-expansion ofMolecular therapy. Methods & clinical development · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. HDAd6/35++ - A new helper-dependent adenovirus vector platform forMolecular therapy. Methods & clinical development · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Human gene therapy · 2022
    Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

C KemperDivision of Rheumatology, Washington University School of Medicine, St. Louis 63110-1093, USA.
M Leung
C B Stephensen
C A Pinkert
M K Liszewski
R Cattaneo
J P Atkinson
Washington University in St. Louis · USMayo Clinic · USUniversity of California, Davis · USUniversity of Rochester · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
MCP--STRUCTURE, MICROBIAL INTERACTIONS AND FUNCTIONR01AI037618 · NIAID · WASHINGTON UNIVERSITY · PI ATKINSON, JOHN · 1995 to 2010
$3.3M
NCI NIH HHS CA13148NCI NIH HHS P30 CA013148NIAID NIH HHS R01 AI037618NIAID NIH HHS R01 AI37618
6 · The paper itself

Abstract

Human membrane cofactor protein (MCP; CD46) is a widely distributed complement regulator. In the mouse, expression of MCP is largely restricted to the testis while a related, widely expressed protein (Crry) appears to perform MCP's (CD46) regulatory activity. We have developed two mouse strains transgenic for human MCP (CD46) utilizing an approximately 400 kb YAC clone carrying the complete gene. A third mouse strain was generated using an overlapping YAC clone isolated from a second library. The expression of human MCP (CD46) in these mouse strains was characterized by immunohistochemistry, FACS, Western blotting and RT-PCR. No differences were detected in the isoform pattern or distribution among the three strains, although the expression level varied according to how many copies of the gene were integrated. The expression profile closely mimicked that observed in humans, including the same pattern of isoform expression as the donor. In addition, tissue-specific isoform expression in the kidney, salivary gland and brain paralleled that observed in man. The transgenic mice expressed low levels of MCP (CD46) on their E, in contrast to humans but in line with most other primates. These mice should be a useful tool to analyse tissue-specific expression, to establish animal models of infections and to characterize the role of MCP (CD46) in reproduction.

Indexed as

AnimalsAntigens, CDBlood CellsErythrocytesFemaleHumansMaleMembrane Cofactor ProteinMembrane GlycoproteinsMiceMice, TransgenicProtein IsoformsReceptors, VirusRNA SplicingSpecies SpecificityTissue DistributionAntigens, CDCD46 protein, humanMcp protein, mouseMembrane Cofactor ProteinMembrane GlycoproteinsProtein IsoformsReceptors, Virus

Identifiers

PMID11422193
PMCPMC1906059
OpenAlexW1965869797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.